Ozempic Side Effects: For many people taking Ozempic, the first unwanted effect is not an unusual laboratory result or a dramatic medical event. It is something much more ordinary: nausea.
That matters because nausea sits at the centre of the semaglutide side-effect story. GoodRx reports that up to 20% of people receiving Ozempic for type 2 diabetes experienced nausea in clinical trials, with the problem becoming more likely at higher semaglutide doses. Vomiting tends to be less common, while nausea and other gastrointestinal symptoms often become more noticeable when treatment begins or the dose is increased.
Most of these reactions are not permanent. Medical News Today lists nausea, vomiting, diarrhoea, abdominal pain and constipation among the more common effects seen in Ozempic clinical trials, noting that such symptoms may last for days or weeks rather than indefinitely.
But the everyday discomfort can obscure a second, more important part of the picture. Semaglutide has also been associated with pancreatitis, gallbladder problems, kidney injury, intestinal complications, diabetic retinopathy and other less common but potentially serious events. The dividing line between an expected digestive reaction and a symptom that needs medical attention is therefore central to using the drug safely.
Why digestive symptoms are so prominent?
Semaglutide belongs to the glucagon-like peptide-1, or GLP-1, receptor agonist class. GoodRx explains that these medicines stimulate insulin release, reduce glucose production by the liver and slow the movement of food out of the stomach. They also act on areas of the brain involved in appetite and fullness.
A 2025 review by Lekha Pillarisetti and Devendra K. Agrawal adds an important pharmacological detail. Semaglutide has a half-life of roughly 165 hours, while the review says the drug can remain in circulation for around five weeks after the final dose. The same review describes delayed gastric emptying as one of semaglutide’s effects, alongside reduced appetite and food intake.
That combination helps put the gastrointestinal complaints into context. GoodRx identifies nausea, vomiting and diarrhoea as the most common semaglutide side effects, while constipation, gas, bloating, stomach discomfort, acid reflux and burping can also occur.
Medical News Today reports that nausea and diarrhoea are most often noticed when Ozempic is first started or following a dosage increase. For most patients, those problems improve within days or weeks. Constipation can emerge at different points during treatment because the medication slows digestion.
Ozempic Side Effects: Dose increases can be a difficult period?
The timing of symptoms is significant because semaglutide doses are generally increased gradually rather than raised all at once.
GoodRx says nausea and vomiting become more likely at higher doses, which is one reason prescribers increase semaglutide gradually over several months. The publication notes that symptoms such as nausea generally become easier to tolerate as treatment continues.
Healthline similarly reports that nausea, vomiting and diarrhoea may be more common during dose increases. Its practical advice for digestive symptoms includes eating smaller and more frequent meals, staying hydrated, avoiding high-fat, greasy or spicy foods, and considering ginger or peppermint tea.
Persistent symptoms deserve more attention. Medical News Today advises patients to speak with a doctor or pharmacist when side effects continue, interfere with everyday life or become severe rather than stopping Ozempic without medical guidance.
The serious complications are less common, but harder to ignore
The risk conversation changes when symptoms move beyond temporary nausea or constipation.
Healthline lists acute pancreatitis, kidney injury, severe stomach problems, gallbladder problems, vision changes, hypoglycaemia, serious allergic reactions and pulmonary aspiration among serious effects reported with Ozempic. It describes serious reactions as generally rare and cites acute pancreatitis in 0.3% of participants in drug studies.
Low blood sugar has an important qualification. Healthline reports that severe hypoglycaemia occurred in between 0.8% and 1.2% of cases when Ozempic injection was used alongside a sulfonylurea such as glipizide, rather than presenting those figures as the risk from Ozempic alone.
Gallbladder disease is another recognised concern. GoodRx says gallstones and other gallbladder problems were reported in fewer than 2% of people using semaglutide in clinical trials. It advises prompt medical attention for symptoms including upper abdominal pain, fever, jaundice or clay-coloured stools.
Kidney problems may also develop indirectly. GoodRx says reported cases of acute kidney damage appear to be primarily connected to severe gastrointestinal symptoms that cause dehydration. Maintaining fluid intake becomes particularly important for people experiencing significant diarrhoea or vomiting.
Pancreatitis remains an area where context matters
Pancreatitis attracts particular attention because it can become life-threatening, but the available evidence is not as simple as saying semaglutide routinely causes it.
The 2025 scientific review notes that case reports of acute pancreatitis exist, while also citing research that found no increased risk of acute pancreatitis when semaglutide was compared with placebo. The authors describe a rare case involving pancreatitis after four years of semaglutide use but stress that further research is needed to understand long-term associations and contributing risk factors.
GoodRx takes a similarly cautious position, stating that pancreatitis has been reported with semaglutide but that it is not yet clear in every case whether the drug itself or another factor is responsible. Severe abdominal pain accompanied by nausea, vomiting or jaundice warrants immediate medical assessment, according to the publication.
Delayed stomach emptying has implications beyond nausea
One of the less obvious concerns surrounding semaglutide appears around surgery and anaesthesia.
The Pillarisetti and Agrawal review discusses cases of pulmonary aspiration in patients receiving semaglutide, linking the concern to delayed gastric emptying and residual gastric contents. In cases cited by the authors, stomach contents were still present despite patients following pre-operative fasting instructions.
The review places pulmonary aspiration alongside pancreatitis, acute kidney injury, acute gallbladder disease, diabetic retinopathy and non-arteritic anterior ischemic optic neuropathy among the severe or rarer adverse effects that require greater clinical awareness.
Gastroparesis and intestinal problems have also entered the discussion. GoodRx reports cases of intestinal paralysis, or ileus, with semaglutide and notes that ileus can in some instances lead to bowel obstruction.
Symptoms of gastroparesis can overlap with ordinary semaglutide reactions, including nausea, vomiting and feeling full after eating, making persistence or worsening of symptoms particularly important.
The thyroid warning needs precise wording
Ozempic also carries the FDA’s strongest category of medication warning concerning thyroid C-cell tumours.
GoodRx states that animal studies found an increased risk of thyroid C-cell tumours with semaglutide, but that the risk has not been confirmed in people.
Medical News Today makes the same distinction. Animal studies found thyroid tumours, but it remains unknown whether Ozempic causes thyroid tumours in humans. The publication says the drug should not be used by people with a personal or immediate family history of medullary thyroid cancer or by those with multiple endocrine neoplasia syndrome type 2.
That distinction is important. A boxed warning signals a serious potential risk, but it does not establish that thyroid cancer has been proven to occur in humans because of semaglutide.
The risk picture has to be weighed against established benefits
Side effects are only one half of the semaglutide story.
The 2025 review found that oral and injected semaglutide have demonstrated benefits in blood glucose control, weight reduction and cardiovascular risk reduction in people with diabetes.
In all of the SUSTAIN trials discussed in the review, the weekly administration of subcutaneous semaglutide resulted in a lowering of HbA1c of 1.5 to 1.8 percent for up to 30 to 56 weeks. The same study mentions the 26 percent decrease in major adverse cardiovascular outcomes in the SUSTAIN-6 trial among high-risk type 2 diabetics.
This is the reason why the question of side effects should not be simplified into whether Ozempic is safe or dangerous. There is sufficient evidence to show that it is a drug that offers significant treatment potential, with a strong possibility of gastrointestinal side effects, which are however manageable, for some patients.
What patients should watch for?
Mild nausea, diarrhoea, constipation or abdominal discomfort commonly improve as the body adjusts, according to both Medical News Today and GoodRx. Symptoms that persist, become unusually severe or begin interfering with normal daily activity should be discussed with a healthcare professional.
Severe abdominal pain, jaundice, major dehydration, significant vision changes, breathing difficulty or symptoms suggesting a serious allergic reaction fall into a different category and should not be treated as routine adjustment symptoms. Healthline and Medical News Today both advise seeking prompt medical care for potentially serious reactions.
For most people who experience side effects, the story is likely to be one of temporary digestive discomfort rather than a severe complication. But semaglutide’s long duration in the body, its effect on digestion and the range of uncommon adverse events reported with treatment make careful monitoring more than a formality.
The clearest message across the available evidence is also the simplest: common symptoms often settle, persistent symptoms deserve a conversation with a clinician, and severe or rapidly worsening symptoms should never be dismissed as just another Ozempic side effect.
Also Read: Avengers: Doomsday Trailer Expected at D23: Release Time, Preview and What to Expect
